BYNFEZIA PEN TM (octreotide acetate) injection, for subcutaneous useInitial U.S. Approval: 1988

BYNFEZIA PEN TM (octreotide acetate) injection, for subcutaneous useInitial U.S. Approval: 1988

BYNFEZIA Pen is a somatostatin analogue indicated for:
• Reduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) [somatomedin C] in adult patients with acromegaly who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses
• Treatment of severe diarrhea/flushing episodes associated with metastatic carcinoid tumors in adult patients
• Treatment of profuse watery diarrhea associated with vasoactive intestinal peptide tumors (VIPomas) in adult patients
Injection: 2,500 mcg/mL octreotide as a 2.8 mL single-patient-use pen
Manufactured By: Sun Pharmaceutical Industries, Inc
Prescribing Information URL: Click Here

Access to BUPHENYL® (sodium phenylbutyrate) Tablets: Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from Medvitaz Pharma Solutions.

Octreotide, sold under the brand name Sandostatin among others, is an octapeptide that mimics natural somatostatin pharmacologically, though it is a more potent inhibitor of growth hormone, glucagon, and insulin than the natural hormone. It was first synthesized in 1979, by the chemist Wilfried Bauer. It was approved for use in the United States in 1988.


There are no reviews yet.

Add a review

Neeraj Nagpal

Head of Operations

 The profound knowledge of more than 20 years in sales and marketing sector, he has been working dedicatedly and contributing to pharmaceuticals industry. He handles all operations over the country.

Contact Our Team

Contact us and we will reply as soon as possible!

    need help?

     MEDVITAZ is an initiative for helping end-users directly to get the right medicines and right medical treatments from the right source.